Erythropoietin (EPO) Drug Market Is Predicted To Grow Quickly Due To The Rising Incidence Of Chronic Diseases Till 2025: Grand View Research, Inc.
The global erythropoietin (EPO) drugs market is
expected to reach USD 17.4 billion by 2025, according to a new report by Grand
View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer
resulting in anemia is a major growth driver of this market.
According to the statistics
published by the National Heart, Lung, and Blood Institute of the U.S.
Department of Health & Human Services, over 3 million people are affected
by anemia every year and this number is expected to increase over the forecast
period. This showcases the need for erythropoietin-stimulating agents in the
coming years.
Introduction of novel drugs and
their cheaper biosimilar formulations with enhanced efficacy and
cost-effectiveness is also expected to serve this industry with lucrative
opportunities. For instance, development of numerous biosimilars in the
European market is expected to gain traction and increase their usage rates,
owing to associated benefits such as less time required for approval,
cost-efficiency, and enhanced therapeutic effect.
Companies are involved in
extensive R&D initiatives for development of innovative molecules and
discovering new therapeutic areas for existing drugs. For instance, in April
2016, Sandoz received approval from the European Commission for use of its
biosimilar Binocrit in nephrology indications, thereby extending the
therapeutic area of its product portfolio.
Moreover, many of the industry
players in the U.S., Europe, and Asia Pacific are involved in the development
of new biosimilars. For example, Biocon’s subsidiary Syngene International
entered into an agreement with Bristol-Myers Squibb to extend their drug
discovery and development program in India. This enables Biocon to enhance its
erythropoietin drugs portfolio. Expected product approvals in the coming years
are anticipated to fuel market growth.
Browse full research report on Erythropoietin (EPO) Drug
Market: http://www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market
Further key findings from the study suggest:
- The biologics segment is declining over the forecast
period owing to patent expiration of branded biologics and introduction of
biosimilars in the market
- The patent for Aranesp (darbepoetin-alfa) will expire
in 2024 in the U.S. and is expected to provide numerous future growth
opportunities for new market entrants
- Epoetin-alfa held the largest share of product
segment owing to its early introduction in the U.S. market and patent
protection
- Epoetin-omega and epoetin-zeta are anticipated to
exhibit lucrative growth over the forecast period owing to associated
benefits such as longer half-life and enhanced therapeutic effects
- Use of erythropoietin drugs for treatment of renal
diseases held a dominant share as of 2016 owing to the increasing
incidence of chronic kidney diseases
- The Asia Pacific regional industry for
erythropoietin-stimulating agents is expected to witness lucrative CAGR
during the forecast period
- Industry participants are focusing on the discovery
of new therapeutic areas for existing drugs and development of
cost-effective biosimilars, thereby increasing R&D activities for the
development of erythropoietin drugs.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the erythropoietin (EPO)
drugs market on the basis of the drug class, product, application, and region:
Erythropoietin Drugs Drug class Outlook (Revenue, USD
Million, 2014 - 2025)
- Biologics
- Biosimilar
Erythropoietin Drugs Product Outlook (Revenue, USD
Million, 2014 - 2025)
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Erythropoietin Drugs Application Outlook (Revenue, USD
Million, 2014 - 2025)
- Cancer
- Hematology
- Renal
Diseases
- Neurology
Erythropoietin Drugs Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
Access Press Release
By Grand View Research: http://www.grandviewresearch.com/press-release/global-erythropoietin-epo-drugs-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment